SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

18 Apr 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated April 18, 2022 titled ‘Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection’.

The above information is a part of company’s filings submitted to BSE.


Zydus Lifesciences Share Price

930.00 -17.10 (-1.81%)
24-Apr-2026 12:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.45
Dr. Reddys Lab 1317.65
Cipla 1284.00
Zydus Lifesciences 930.00
Lupin 2270.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×